Merck KGaA, Darmstadt, Germany

498 articles with Merck KGaA, Darmstadt, Germany

• Merck KGaA, Darmstadt, Germany, Announces Retirement of Luciano Rossetti, Global Head of R&D for Healthcare

  10/15/2020

   Merck KGaA, Darmstadt, Germany , a leading science and technology company, today announced that Dr. Luciano Rossetti, MD, will be retiring as Global Head of Research

• Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note

  10/9/2020

  Precigen, Inc. (Nasdaq: PGEN), today announced that leading science and technology company and existing shareholder Merck KGaA, Darmstadt, Germany, through its wholly owned subsidiary, Ares Trading S.A., has elected to voluntarily convert a convertible note with an outstanding principal balance of $25 million

• 

  Merck KGaA Diversifies with First Female CEO

  9/29/2020

  The German company announced that the new CEO will take the reins in May 2021.

• BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

  9/18/2020

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.

• EMD Serono Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020

  9/13/2020

  New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer

• Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

  8/25/2020

  Sutro Biopharma, Inc. announced that it has achieved a clinical supply milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany and is entitled to receive a milestone payment.

• 

  Clinical Catch-Up: August 3-7

  8/10/2020

  It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.

• Merck KGaA, Darmstadt, Germany Selects Cambridge Semantics as Enterprise Data Fabric Provider

  7/16/2020

  Cambridge Semantics Aiding Merck KGaA, Darmstadt, Germany in Modernizing its Data Integration Capabilities and in Forging Multiple Data-driven Initiatives BOSTON--( BUSINESS WIRE )-- Cambridge Semantics, the leading provider of modern, graph-driven data integration for the enterprise data fabric, today announced that Merck KGaA, Darmstadt, Germany and its US-based biopharmaceutical business EMD Serono, have selected Cambridge Semantics as its dat

• 

  Biopharma Update on the Novel Coronavirus: July 8

  7/8/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.

• Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical's ASP-1929 antibody-drug conjugate

  7/7/2020

   Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt, Germany under which Merck KGaA,   Darmstadt, Germany will provide cetuximab to Rakuten Medical for its ASP-1929 program. Rakuten Medical uses cetuximab in an intermediate form as the antibody component in its product c

• Immutep Reports First Results from INSIGHT-004 Study

  5/31/2020

  First data from this collaboration study with Merck KGaA, Darmstadt, Germany, and Pfizer Inc and sponsor, IKF, presented at ASCO

• New England Journal of Medicine Publishes Primary Analysis of VISION Data for Tepotinib in Advanced NSCLC with METex14 Skipping Alterations

  5/29/2020

  First publication of primary analysis shows robust and durable clinical response in patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations; data also presented during ASCO 2020

• Merck KGaA, Darmstadt, Germany, and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living with MS

  5/28/2020

  Merck KGaA, Darmstadt, Germany, and Twitch collaborate on World MS Day to increase understanding of the impact of multiple sclerosis (MS)

• Genome & Company receives FDA IND clearance for GEN-001, its first anti-cancer microbiome therapeutic

  4/20/2020

  Asia's first company to sponsor clinical trial of combination therapy of anti-cancer microbiome and anti-PD1/anti-PD-L1 drug

• EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

  4/9/2020

  Breakthrough Therapy Designation and Submission based on positive Phase III JAVELIN Bladder 100 study results

• TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations

  3/25/2020

  EMD Serono announced that the Japanese Ministry of Health, Labour and Welfare has approved TEPMETKO®* for the treatment of patients with unresectable, advanced or recurrent non-small cell lung cancer with MET exon 14 skipping alterations.

• Merck KGaA, Darmstadt, Germany, to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 18th March 2020

  3/16/2020

  Merck KGaA invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

• 

  EMD Serono and Pfizer Halt Phase III Head and Neck Cancer Trial

  3/13/2020

  The companies jointly announced that their Phase III JAVELIN Head and Neck 100 trial of Bavencio (avelumab) with chemoradiotherapy for untreated locally advanced squamous cell carcinoma of the head and neck was unlikely to hit the primary endpoint.

• Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc.

  2/11/2020

  Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY.

• EMD Serono Receives Positive Recommendation for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis from the Institut national d'excellence en santé et en services sociaux (INESSS)

  2/6/2020

  This decision brings PrMAVENCLAD® (cladribine tablets) closer to broader access for eligible patients living with Relapsing-Remitting Multiple Sclerosis in the province of Quebec